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Abbreviations 
AC, arrhythmogenic cardiomyopathy 
ARVC, arrhythmogenic right ventricular cardiomyopathy  
CMR, cardiac magnetic resonance 
ECG, electrocardiography 
EF, ejection fraction 
FAC, fractional area change 
GLS, global longitudinal strain 
LBBB, left bundle branch block 
LGE, late gadolinium enhancement 
LV, left ventricular 
MDCT, multidetector computed tomography 
PET, Positron emission tomography 
PLAX, parasternal long axis view 
PSAX, parasternal short axis view 
PVC, premature ventricular complexes 
SPECT, Single-photon emission computed tomography  
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RV, right ventricular 
RVOT, right ventricular outflow tract 
SCD, sudden cardiac death 
SCMR, Society of cardiac magnetic resonance 
STE, speckle tracking echocardiography 
TFC, Task Force criteria 
VT, ventricular tachycardia  
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1. Current knowledge  
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited 
cardiomyopathy predisposing to ventricular arrhythmias, sudden cardiac death (SCD) and more 
rarely ventricular dysfunction and heart failure. Due to the frequent involvement of the left 
ventricle (LV) the term arrhythmogenic cardiomyopathy (AC) has recently been proposed to 
encompass both LV and RV disease and this expert consensus group acknowledges and 
recommends replacing ARVC with AC.   
The 2010 Task Force Criteria (TFC 2010) have improved the sensitivity of AC diagnosis 
and combine data from different categories including imaging, electrical parameters from resting 
electrocardiogram (ECG) and Holter monitoring, family history, genetic testing, and tissue 
properties(1). Imaging modalities include angiocardiography, echocardiography and cardiac 
magnetic resonance (CMR), with qualitative assessment of RV wall motion abnormalities. In 
addition, a few quantitative measures are included in diagnosis with cut-off values for the RV 
outflow tract (RVOT) diameter and RV fractional area change (RV-FAC) by echocardiography 
and RV ejection fraction (RV-EF) by CMR.  
Being a progressive cardiomyopathy, repeated cardiac imaging is needed in AC patients 
to follow disease progression and importantly, for risk assessment of life threatening ventricular 
arrhythmias. This expert consensus document will give clinical recommendations for how to use 
multi-modality imaging in the different aspects of AC disease, including diagnosis, follow -up, 
risk assessment and differential diagnosis.  
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2. Definition and Pathogenesis of AC   
a. Anatomy and morphology 
AC is a cardiomyopathy characterized by an acquired and progressive replacement of the 
ventricular myocardium by fibrous and fatty tissue (2, 3). The process starts from the epicardium 
or mid-myocardium and then extends to become transmural in the RV, leading to wall thinning 
and aneurysms, typically located at the inferior, apical and infundibular walls (“triangle of 
dysplasia”). The RV involvement can be either segmental or diffuse. The LV involvement is 
present in more than half of the cases, typically located in the subepicardium or mid-
myocardium, and often confined to the postero-lateral region (2); a circumferential distribution is 
also observed. Hearts with isolated or predominantly LV involvement have been reported. The 
septum is affected in a minority of cases, typically on the right side. Fatty infiltration is not 
sufficient to achieve a clear-cut diagnosis and replacement-type fibrosis and myocyte 
degenerative changes are essential (4). Inflammatory cell infiltrates, together with myocyte 
injury, are often observed in the early stages of disease and during the process of evolution, 
mimicking myocarditis (2, 5, 6)  
b. Pathogenesis, genetic background and inheritance.   
Dysontogenetic (dysplasia), inflammatory (myocarditis), and degenerative (myocardial 
dystrophy) theories have been proposed as the mechanisms of AC(2). A familial background 
consistent with autosomal-dominant inheritance is present in most AC patients (7, 8). Recessive 
families with cardiocutaneous manifestations (palmoplantar keratoderma and woolly hair) have 
been reported and have provided the substrate for the initial recognition of disease causing genes 
(Naxos disease, Carvajal syndrome) (9, 10).  Up to 50-60% of probands harbor a disease-causing 
gene mutation, leading to the current belief of a genetically-determined “cardiomyopathy“. 
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Disease-causing genes mostly encode major components of the cardiac desmosomes and include 
plakoglobin, JUP; desmoplakin, DSP; plakophillin-2, PKP2; desmoglein-2, DSG2; and 
desmocollin-2, DSC2 (6). Compound/digenic heterozygosity was identified in up to 25% of AC-
causing desmosomal gene mutation carriers, in part explaining the phenotypic variability. Non-
desmosomal genes, including transforming growth factor beta-3, TGFβ3; desmin, DES; catenin-
aT, CTNNA3; phospholamban, PLN; Lamin A/C,  LMNA; titin, TTN have been reported, 
though the phenotypes often differ from classical AC(11). 
How the mechanical and/or functional disruption of cell junctions by mutant desmosomal 
proteins leads to cardiomyocyte death and subsequent repair with fibrous and adipose tissue is 
under investigation. Abnormal cell-cell adhesion as well as intracellular signaling pathways (Wnt 
and Hippo/YAP) have been implicated in adipogenesis, fibrogenesis and apoptosis. Finally, gap 
junction and ion channel remodeling have also been demonstrated, suggesting that impaired 
mechanical coupling might account for abnormal electrical coupling (11, 12). 
Key points: 
• Arrhythmogenic cardiomyopathy is a progressive disease. Morphological changes 
start from the epi- or mid-myocardium and usually progress through all layers as a 
transmural myocardial disease 
• The left ventricle is affected in >50% of cases and the term “arrhythmogenic 
cardiomyopathy” has been proposed to include biventricular disease  
• A genetic mutation is found in up to 50-60% of probands, mostly affecting 
desmosomal genes 
• Inheritance is most frequently autosomal dominant 
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3. Clinical characteristics  
a. Symptoms and ECG 
Family studies suggest that most individuals carrying potentially disease causing variants 
go undiagnosed(13).  Data on clinical presentation will depend on the sources, ranging from the 
primary care physician to the coroner’s pathologist.  The classic clinical presentation is with 
exercise related ventricular tachycardia (VT) associated with awareness of rapid heartbeat, 
lightheadedness and/or syncope. Palpitation, when described, is of sudden onset and offset, rapid 
and different from the awareness of a ‘heavy heart beat’ typical of ventricular ectopic beats(5).  
Atypical chest pain which is precordial, but neither exertional nor relieved by rest, is reported in 
publications from referral centers, and may initially focus investigations on the exclusion of 
coronary artery disease.  The mechanism is uncertain, but may relate to inflammation associated 
with a potential arrhythmic or hot phase of the condition. 
The earliest disease manifestations are usually seen on the ECG, while the structural 
abnormalities which are best identified with imaging occur later in the natural history of the 
disease (14). Twelve lead ECG changes reflect myocardial areas of disease involvement.  AC 
involving the RV free wall will typically manifest with inverted T waves in V1 to V3, and where 
there is LV involvement the T wave inversion may extend to lateral chest leads (V4-V6).  T wave 
changes in inferior leads (II, III, aVF) often reflect RV infero-posterior wall involvement.  Most 
patients present in sinus rhythm with a normal QRS axis, normal PR and QRS intervals, though a 
delayed upstroke of the S wave may be a subtle early disease manifestation, and is considered 
minor AC diagnostic criterion(1, 15).  A normal ECG may occur in a mutation carrier, but in 
these individuals the risk of a life-threatening event as the initial clinical manifestation is very 
low.  Similarly and importantly, a diagnosis based on imaging criteria with completely normal 
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ECG should be considered suspicious, and warrants careful review. AC with morphological 
changes limited to or predominately affecting the LV is increasingly recognized (6, 16-18).  Such 
patients may have inferior and/or lateral T-wave inversion and ventricular arrhythmias with a 
configuration suggestive of a LV origin, often from the posterior lateral LV wall.  In contrast, 
ventricular ectopy with left bundle branch block (LBBB) morphology, particularly with a 
superior axis, is typical of ARVC. LBBB morphology ectopy/ventricular arrhythmia with an 
inferior axis (R wave positive in leads II and III and negative in lead aVL) requires careful 
evaluation and differentiation from RVOT tachycardia, a condition which is not familial and 
rarely life-threatening.  Ambulatory ECG monitoring during normal daily activity, ideally with 
12 lead recordings, is an important diagnostic evaluation and often reveals ventricular arrhythmia 
in the absence of symptoms in affected individuals.  The signal averaged ECG provides a marker 
of slow conduction and arrhythmic risk, but is neither a sensitive nor specific diagnostic test (19). 
Key points: 
• The classical clinical presentation is the occurrence of ventricular arrhythmias, 
typically with LBBB morphology and superior axis 
• LBBB morphology ventricular arrhythmias with an inferior axis requires careful 
evaluation and differentiation from the more benign RVOT tachycardia 
• ECG changes are often the first manifestation and a diagnosis based on imaging 
criteria with completely normal ECG should be considered suspicious 
4. Structural remodeling in AC - RV/LV dominant types 
Echocardiography and CMR are pivotal to detect structural and functional abnormalities 
in patients with suspected or genetically proven AC. Angiocardiography is also included in the 
TFC 2010, but it is an invasive procedure, now rarely performed. The importance of high 
sensitivity non-invasive tools for diagnosing early disease is emphasized by the fact that SCD 
may occur in individuals with no or subtle evidence of structural heart disease. Accordingly, it is 
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important to distinguish between individuals with early, pre-symptomatic disease, where no or 
minor and subtle structural changes can be detected in a single specific region of the RV (inflow 
tract, outflow tract, or apex, the “triangle of dysplasia”) and symptomatic individuals with 
advanced disease, where severe RV involvement is evident, with or without LV involvement, 
typically affecting the posterior lateral wall. On the other hand, specificity is also important and 
in subjects with non-specific symptoms and/or subtle abnormalities, over-diagnosing, especially 
by non -experienced operators, must be avoided.  
According to the TFC 2010 (1) the cardiac imaging diagnosis of AC is based on RV 
global or regional dysfunction and structural changes, with or without associated LV dysfunction 
(Table 1). Compared to previously published diagnostic criteria (20), TFC 2010 imaging criteria 
increased sensitivity to around 70%, keeping specificity high (around 95%). According to the 
TFC 2010(1), regional RV wall motion abnormalities are the main imaging criteria to diagnose 
AC, and the level of RV dilatation and RV global dysfunction determines whether or not a major 
or minor AC criterion is present. Despite the undisputed usefulness of the TFC 2010 criteria as a 
diagnostic tool for AC, concerns have been raised about its practical applicability as a screening 
tool. These include the complexity of the diagnostic workup, the necessity of memorizing several 
different imaging cut-off values both for major and minor criteria, the non-inclusion of RV 
inflow tract data and the low sensitivity of  conventional echocardiographic criteria for the 
detection of subtle regional RV wall abnormalities in early disease stages (21).  
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a. Echocardiography  
i. Conventional echocardiographic methods 
Echocardiography is the first line imaging modality in AC, and the most commonly used 
imaging tool for follow-up of AC patients. Echocardiography is unexpensive, widely available 
and well tolerated. However, the echocardiographic diagnosis of AC is challenging and needs 
specific expertise. The echocardiographic protocol requires more views than those usually 
included in a routine study. Segmental evaluation of the RV is difficult due to the complex shape 
of the chamber and the position of the RVOT immediately under the sternum, narrowing the 
acoustic window for proximal structures. Moreover, the quantitative analysis of RV function is 
also difficult due to the complex RV anatomy and to its load dependency. A systematic 
qualitative assessment of RV function and dimensions should be performed initially, followed by 
quantitative measurements using conventional and advanced echocardiography (22, 23). 
The typical morphological features in AC patients are RV dilatation, regional wall motion 
abnormalities or global RV dysfunction. The TFC 2010 (1) only includes only two-dimensional 
echocardiography as imaging criteria to diagnose AC: presence of RV akinesia, dyskinesia, or 
aneurysms together with measurements of RVOT diameter and RV FAC (Figure 1 and 2).  
The RVOT diameter (1, 22, 23) can be measured from parasternal long axis (PLAX) 
(Figure 1) or from parasternal short axis (PSAX) views. When possible, the proximal RVOT 
diameter should be measured measured from PSAX.  Measurements of RVOT diameter from 
PSAX are more robust and reproducible than from the long axis view (Figure 1B). Furthermore, 
the measurement of the ratio between the proximal RVOT and the aortic root diameter may be 
also assessed (24) with larger ratios indicating AC.  
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In addition, we recommend the routine and systematic assessment of RV inflow 
measurements in AC (Ref Leren JACC CVI in press)(RV basal diameter obtained from RV 
focused 4-chamber view, Figure 1C), as well as the inclusion of additional quantitative echo-
strain data. (Table 2) The new parameters are reported in one or two studies (25-28) and are not 
validated in larger or multicenter studies. However, careful assessment of RV morphology and 
function will add to the accuracy of AC diagnosis. 
ii. Advanced echocardiographic methods  
New echocardiographic techniques may increase the performance of conventional 
echocardiography. Despite its intrinsic limitations, such as angle dependency and time consuming 
analysis, Doppler tissue imaging is useful in the assessment of RV longitudinal systolic function 
(peak velocity of the systolic (s') velocity of lateral tricuspid annulus in apical 4-chamber view, 
s’) (Figure 3). RV function can be further assessed by speckle tracking echocardiography (STE), 
traced from the 4-chamber view with focus on the RV.  RV peak systolic longitudinal strain 
values from six RV segments are averaged to calculate RV global longitudinal strain (RV GLS) 
(Figure 4). Alternatively, peak systolic strains from three RV free wall segments are averaged as 
a measure of RV free wall strain (29). Both RV GLS and RV free wall strain have been reported 
to be reduced in the early phases of AC (25-28). In addition to amplitude parameters, temporal 
parameters such as the time to peak strain (time from onset R on ECG to maximum RV 
longitudinal shortening by STE) should also be assessed. RV Mechanical dispersion may be 
calculated as the standard deviation of time to peak strain in a 6 RV segment model (26) (Figure 
5) or in a 3 segments model (25) (Table 2). 
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iii. Three-dimensional echocardiography 
 Three-dimensional echocardiography (3DE) allows measurements of RV volumes 
overcoming the limitations of conventional 2D views with respect to orientation and reference 
points. RV and LV volume measurements will be of interest in patients with overt AC, while 
increased volumes are rare in early phases of AC. Three-dimensional echocardiography can 
obtain a reasonably accurate estimate of RV volumes and provide RV EF, but expertise is needed 
and practical recommendations regarding RV acquisition and analysis by 3DE have to be 
followed. Technical challenges include particularly patients with imperfect image quality or 
advanced AC patients with severely enlarged RV (Figures 6-10). Normal 3DE values of RV 
volumes are available (23, 30). However, no data currently exist for AC patients. Although 3DE 
tends to underestimate RV volumes, excellent correlations with CMR have been described (31).  
According to current guidelines, in laboratories with appropriate 3D platforms and experience, 
3DE-derived RV EF should be considered as a method of quantifying RV systolic function. 
Roughly, an RV EF lower than 40- 45% usually reflects abnormal RV systolic function. (22, 23) 
In summary, we recommend a broader approach of imaging methods than the current 
TFC, considering the inclusion of specific indications for imaging methods in probands (index 
patients, presenting with overt disease), follow- up of probands, and in family screening and in 
follow up of mutation positive family members (Chapter 7). Abnormal RV or LV function by 
other parameters will probably strengthen the suspicion of AC in unclear cases. In addition to 
parameters used in the TFC, we propose to evaluate additional parameters in patients with 
suspected or established AC. These parameters are not yet proven to increase diagnostic 
sensitivity but should be evaluated to prospectively gain new data in AC. 
 - Conventional echo parameters:  TAPSE and RV basal diameter (REF Leren in press). 
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-Advanced echo parameters: RV GLS, LV GLS and mechanical dispersion by 2D-STE 
(26, 32), in family screening and follow up of mutation positive family members in which 
sensitive echocardiographic parameters are needed.  
-  Three-dimensional echocardiography parameters. However, the value of 3DE and cut 
off values for AC diagnosis and risk stratification need to be established. 
Finally, new cut-off limits need to be considered and should be based on data from 
multiple large cohorts.  
Key points: 
• RV wall motion abnormalities in addition to quantitative measurements of RVOT 
diameter and RVFAC are the echo parameters included in the TFC 2010 
• We recommend a broader, comprehensive and systematic assessment of RV 
geometry and function using both conventional and advanced echocardiographic 
techniques  (Table 1) 
b. CMR  
CMR is less available and more expensive than echocardiography. However, in centres 
with adequate CMR equipment and expertise, the accuracy of CMR to detect subtle RV regional 
functional and structural wall abnormalities has been shown to be higher than conventional 2D 
echocardiography, due to the higher spatial resolution of the former(21). The tomographic, high-
spatial resolution, non-invasive tissue characterization nature of CMR is particularly suited for 
the assessment of cardiomyopathies, including AC. CMR is erroneously considered the “gold 
standard” test to diagnose AC. As the TFC 2010 (1) emphasizes, the diagnosis of this disease is a 
composite of familiar, ECG, arrhythmic, histological, functional and structural features, in which 
CMR may play a role only to the latter two aspects. Great caution must be employed when the 
only abnormality in a presumed AC patient is found at the level of the RV on CMR, as it is 
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uncommon for AC patients to have a normal ECG and Holter monitoring but an abnormal CMR 
exam (33).  
The CMR parameters from the TFC 2010 include RV regional dysfunction, reduced RV 
EF and enlarged indexed RV end-diastole volume, as well as localized RV wall thinning and 
aneurysmal formations (Figure 11 and 12). Despite the ability of CMR to detect myocardial 
fibro-fatty replacement in current routine clinical practice with the late gadolinium enhancement 
(LGE) and gradient echo with fat saturation technique, respectively, this aspect is not included in 
the TFC 2010 as a diagnostic criterion. In fact, at the time of compiling the 2010 TFC, fibro-fatty 
replacement by CMR was not considered a robust parameter that could be consistently 
reproduced in different laboratories. Moreover, the lack of a control population was considered a 
major drawback. With the improvement in imaging quality and the adoption of standard 
acquisition protocols, it remains to be seen whether fibro-fatty replacement by CMR will be 
considered in future reiterations of the TFC. CMR play also an important role in detecting AC 
phenocopies: unrecognized disease that could mimic AC such as cardiac displacement, RV 
volume overload, and myocardial scarring (identified in up to 4.6% of patients in a large cohort 
of 657 patients with suspected AC). (34)  
Of note, the TFC 2010 lack specific diagnostic criteria for the non-classical variant of AC, 
which includes the dominant or isolated LV disease. This entity can be under-diagnosed and the 
abnormalities be attributed to other disorders, such as myocarditis, dilated or hypertrophic 
cardiomyopathy. CMR can identity LGE in a subepicardial/mid-wall distribution confined to the 
LV(18) . 
Current CMR major criteria are shown in Table 1. 
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The value of CMR in children has also been recently reported and supported the good 
sensitivity of CMR in AC diagnosis. Furthermore, this study showed that fibro fatty replacement 
is rare in children with AC. (35) 
Protocol in supplemental file 
Key points: 
• RV wall motion abnormalities in addition to RV volumes and RVEF are the CMR 
diagnostic criteria included in the TFC 2010.  
• LGE on CMR is an important sign of disease and can be the only sign of  LV 
involvement 
• CMR alterations alone, without ECG and Holter abnormalities, are uncommon in 
AC disease except for the LV variant 
 
c. CT  
Cardiac CT is not included in the diagnostic algorithm and thus usually is not part of the 
initial screening of patients with suspected AC. Nevertheless, multidetector computed 
tomography (MDCT) has an excellent spatial resolution and allows accurate quantification of RV 
and LV volumes/function and, similar to CMR, detection of fatty tissue in the myocardium (ref 
34). Currently, low radiation dose scan can be performed (1 to 2 mSv), while maintaining good 
temporal and spatial resolution (36).   
According to the 2010 ACC/AHA appropriate use criteria (37), MDCT is appropriate for 
the evaluation of structural RV and/or LV remodeling in suspected AC, in particular for those 
patients with inadequate echocardiographic images and contraindications for CMR (36). Relevant 
MDCT parameters include RV dilatation, reduction of RV EF, severe segmental dilatation, and 
regional hypokinesis which are part of the major or minor criteria for the diagnosis of AC (1)(ref 
33). In addition the visualization of epicardial and intramyocardial fat helps to assess 
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biventricular involvement. Thus MDCT can be helpful to differentiate between AC and other 
causes of ventricular arrhythmia (38) and could be used before epicardial ablation to localize both 
RV (39) and LV (40) fat related arrhythmic substrate. 
CT protocol in supplemental file 
d. Radionuclide angiography/SPECT/PET 
 
Nuclear imaging is not included in the diagnostic algorithm of patients with suspected 
AC. Radionuclide angiography may provide measurements of RV volumes, RV ejection fraction 
and the standard deviation of regional times of end systole which can help to recognize diffuse or 
localized forms of AC (41) in patients with ventricular arrhythmias when the acoustic window is 
inadequate for echocardiography and the patient has contraindications to CMR(42). 
Abnormal presynaptic myocardial sympathetic function, demonstrated using 123I-MIBG 
SPECT, is associated with a markedly higher risk of future recurrent life-threatening ventricular 
tachyarrhythmias both in patients with heart failure and in patients with AC (43, 44). These 
findings are associated with downregulation of LV myocardial b-adrenergic receptor density, 
demonstrated by 11C-CGP-12177 PET (45). Nuclear imaging of myocardial sympathetic 
function may therefore help for individualized risk stratification in AC independently from other 
common structural features. 
Key points: 
• MDCT is appropriate for the evaluation of structural remodeling in patients with 
suspected AC who have inadequate echocardiographic images and 
contraindications for CMR 
• Nuclear imaging may be a potential risk stratification tool, but it still a research 
tool and needs further investigation  
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5. Role of imaging in early disease  
a. Early signs 
The overt stage of AC is preceded by a concealed stage with minor no or minor signs of 
disease. However, life-threatening arrhythmias can occur with only discrete myocardial structural 
changes (28, 46-49). On the other side, presence of structural abnormalities highly increases the 
risk of ventricular arrhythmias. Echocardiography is the first line imaging modality in AC. 
However, the diagnosis is more difficult at the early stage of the disease when only mild RV 
hypokinesia and dilatation are present (24, 47, 50). In this situation, additional information can be 
obtained from CMR, strain echocardiography (26, 51), and potentially from 3DE (52), although 
the latter two imaging techniques are not included in the current TFC 2010 since data are still 
either missing or limited. Teske et al. (28) focused on early detection of AC and found abnormal 
RV strain in 71% of asymptomatic carriers. A dilated RV basal diameter and pronounced RV 
mechanical dispersion may be other early echocardiographic signs of AC disease (Table 2). (25, 
26, 53)  
The role of CMR is important and it is the preferred imaging modality in the early 
diagnosis of AC, providing assessment of function and tissue characterization of both ventricles. 
Late gadolinium enhancement (LGE) is used to assess myocardial fibro-fatty replacement which 
may help to diagnose AC, although LGE is not specific for AC and may be present also in other 
cardiomyopathies (47). Table 3 reports the advantages and limitations of the imaging techniques. 
Key points 
• Advanced echo modalities and CMR are the preferred imaging techniques in the early 
diagnosis of AC, allowing to detect subtle changes in biventricular function and tissue 
characterization 
21 
 
6. Imaging in risk stratification of ventricular arrhythmias  
Severely reduced RV function and LV involvement are important risk factors for 
ventricular arrhythmias in AC.(54) RV dilatation, reduced TAPSE and low FAC have been 
associated with arrhythmic risk in two studies (26, 50).  Also right atrial dilation and tricuspid 
regurgitation have been related to arrhythmic events in one study on AC (50). Based on these and 
other findings, patients with abnormal RV function (Table 2) should be followed closely and be 
continuously evaluated for ICD implantation (48). The role of right chamber volume 
modifications for risk stratification of arrhythmias is controversial. In some cohorts RV EF and 
RV end-diastolic volume did not change significantly during long-term follow-up. (7, 55, 56) 
Importantly, involvement of LV function is a strong marker for risk of ventricular arrhythmias. 
In comparison with echocardiography, CMR has the advantage of a better diagnostic 
accuracy of RV regional wall motion abnormalities, a characteristic with definite implications for 
risk stratification. A single study has indicated that an impairment of adrenergic innervation 
(obtainable by 123I-MIBG) was associated with a higher incidence for future recurrences of VT 
 in AC patients (44) as discussed above (Chapter 4d). This finding needs to be further 
investigated. To date, cardiac CT has not shown power in predicting VT in AC patients.  
Table 4 summarizes advantages and disadvantages of the current imaging tools for risk 
stratification of VT in AC.  
Key points 
• Presence of any morphological or functional abnormalities in combination with 
electrical changes are the basis of AC diagnosis and indicate increased risk of 
ventricular arrhythmias.  
• Risk stratification is commonly performed on an individual basis and definite 
evidence based parameters are lacking.  
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7. Imaging follow up in AC  
Patients with AC and their family members should be followed clinically and undergo 
imaging testing on a regular basis, preferably at tertiary referral hospitals with specific experience 
in managing patients with AC(57). In order to maximize the sensitivity and specificity for 
correctly diagnosing AC it is essential that all diagnostic imaging options are used in a rational 
and comprehensive way, in order to establish 
a) AC diagnosis  
b) AC disease staging and progression  
c) Risk assessment of ventricular arrhythmias  
d) Assessment of heart failure and evaluation for cardiac transplant. 
 Among the different non-invasive cardiovascular imaging modalities, only 
echocardiography and CMR have been included in the TFC 2010(1). Other modalities with 
potential role in follow up of AC disease may be MDCT and 123I-MIBG SPECT as discussed 
above. 
Imaging modality and follow up intervals differ between AC probands, family members 
and patients with ICD. In probands (index- cases of AC, presenting with overt disease), RV 
structural changes are usually present and the diagnosis is often made with echocardiography 
alone. CMR may also be performed at the initial diagnosis, if available, for a better morphologic 
and functional characterization, particularly if ICD is planned. CMR is mandatory in selected 
cases where the diagnosis depends on the presence or absence of imaging criteria and to assess 
the LV involvement by LGE CMR. However, probands have often experienced a life-threatening 
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ventricular arrhythmia and are often implanted with an ICD. Newer ICDs are CMR conditional 
(i.e. patients can be safely scanned following a specific protocol). During follow- up, 
echocardiography is repeated at regular intervals (Table 5) and CMR should be repeated if 
changes in clinical status and in questions not answered by echo. Family screening and follow -
up of mutation positive family members, usually include individuals with no or only subtle 
morphological and functional findings. Because of the low sensitivity of echocardiography, both 
echo and CMR must be used to detect early phenotypes of the disease and repeated at regular 
time intervals (21, 57).  
Importantly, there is no current evidence to guide the use of imaging during follow-up of 
patients with definite or possible diagnosis or in patients at-risk of AC. The following 
recommendations are based on cost-effectiveness considerations and consensus among members 
of the writing committee.   
a. Patients with AC, implanted with ICD 
AC patients implanted with ICD are often probands and imaging is used to establish AC 
diagnosis and to follow disease progression. These patients are normally followed with ICD 
checks every 6-12 months. Echocardiography should be performed to detect progressive LV heart 
failure and help evaluation for potential start of heart failure treatment. Furthermore, in AC 
patients with severe RV or biventricular failure, close echocardiographic follow -up may be 
needed for timing of heart transplantation. CMR is usually contraindicated (except in those with 
CMR conditional devices) and is not useful for clinical/management purposes if the diagnosis is 
already established. 
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b. Patients with definite diagnosis of AC and no ICD 
In patients with a definite diagnosis of AC who are not implanted with an ICD, close 
follow- up is necessary. The potential need for ICD implantation must be discussed with the 
patient and considered at each visit.  Careful evaluation of ECG, signal averaged ECG, Holter, 
CMR and echocardiographic changes are warranted. Patients must be informed to contact their 
referral centre if they experience palpitations, syncope or chest pain and these symptoms should 
lead to timely investigation and often ICD implantation. We propose at least yearly follow up 
visits including ECG and Holter and with a low threshold of new visits if the patient reports any 
new symptoms. Accordingly, echocardiography should be performed in all patients with definite 
diagnosis of AC who report changes in clinical status or in whom ECG changes are detected. 
These patients should be submitted to comprehensive echocardiography studies (including 
quantitative assessment of RV and LV size and function, RV outflow tract diameter, Table 2). 
Structural and functional changes in RV and LV are associated with higher risk of ventricular 
arrhythmias with higher risk along with more pronounced changes. It seems reasonable to repeat 
echocardiography every 2-3 years in clinically stable patients. For CMR measures, no cut- off 
values are established indicating when primary prophylaxis ICD implantation is indicated. 
Therefore the repeated use of CMR is currently not indicated. However, LGE LV involvement 
and progressive RV dysfunction indicate progression of disease and thereby higher risk of 
arrhythmias. CMR may therefore be appropriate to perform at first visit and to repeat every 5 
years and on an individual basis. (57)  
c. Mutation-positive family members, early diagnosis 
The follow-up strategy for mutation positive family members of patients with AC or first 
degree relatives from families without identified mutations remains to be defined. Penetrance of 
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disease in family members is approximately 35% (58)and efforts should aim at identifying these 
individuals. ECG changes often precede overt morpho-functional abnormalities of the RV, and 
only small changes in conventional imaging parameters are expected during follow- up of family 
members. (59, 60). Importantly, the finding of morpho-functional abnormalities in family 
members should lead to close follow- up due to the increased risk of ventricular arrhythmias (48). 
However, tissue alterations, forming the substrate for ventricular arrhythmias, may be present 
although no wall motion abnormalities or RV dilatation are detected by conventional imaging 
parameters and technique.  The tissue substrate may potentially be detected by LGE CMR and 
strain echocardiography(61). The delay in myocardial electrical activation and contraction 
inhomogeneity due to subtle tissue alterations could be detected by measuring RV mechanical 
dispersion by speckle tracking echocardiography (26, 62).  We recommend CMR at baseline and 
for follow up at every 1-2 year in younger mutation positive family members either with 
borderline findings or without any symptom/sign of the disease. In asymptomatic mutation 
positive family members > 40 years of age, CMR could be repeated at longer intervals. Detection 
of CMR abnormalities during follow-up may further lead to closer follow up with ECG and 
Holter monitoring and evaluation of prophylactic ICD implantation. Follow up of family 
members should start from age 10, since events before this age are extremely rare.  
Key points: 
• Imaging follow up strategies differ between AC patients with and without ICD 
and in family members 
• Imaging in AC patients with ICD should focus on disease progression in order to 
start heart failure treatment or initiate evaluation for transplantation 
• AC patients with definite or possible diagnosis without ICD should be closely 
monitored due to high risk of arrhythmias. Worsening of imaging findings should 
tend to close arrhythmia monitoring or ICD implantation 
• AC family members should undergo full non invasive testing at first visit and be 
followed with ECG and Holter. Imaging should be repeated if changes in clinical 
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status or ECG and be routinely repeated every 1-2 years in mutation carriers with 
borderline ARVC diagnosis and  every 3-5 years in patients without any clinical, 
ECG or morphological findings. 
8. Other diagnostic modalities in AC and shortcomings of TFC 2010  
Updated diagnostic criteria were published in 2010 to improve sensitivity, but with the 
important prerequisite of maintaining diagnostic specificity. Quantitative imaging cut-off points 
to define a normal RV, to categorize the various degrees of morphofunctional abnormalities, for 
tissue characterization by endomyocardial biopsy, ECG, and signal-averaged ECG have been 
introduced. Genetic data have been also incorporated. However, although the TFC 2010 criteria 
acknowledge the existence of a broad disease spectrum, that includes also LV and biventricular 
subtypes, the revised criteria are addressing only the classical RV variant. No specific diagnostic 
guidelines do exist for the LV involvement, with the exception of: a moderate-to-severe LV 
dysfunction on imaging; lateral or inferolateral T-wave inversion (leads V5, V6, LI, and aVL) and 
low voltage QRS complex on standard limb leads on ECG; and right bundle branch 
block/polymorphic ventricular arrhythmias. 
CE- CMR is increasingly used to provide noninvasive tissue characterization of the RV 
myocardium but it is not included in diagnostic criteria due to the absence of proper control data. 
In addition to the identification of RV involvement, this technique can help to identify early or 
minor LV involvement, even in the absence of morphofunctional abnormalities detected by 
echocardiography (63).  
Endomyocardial biopsy has been proposed for AC diagnosis in cases who remain 
undetermined after extensive non-invasive testing and in patients with suspected AC phenocopies. 
Transthoracic echocardiography is normally performed before biopsy to evaluate RV wall 
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thickness and preexisting pericardial effusions. After biopsy, transthoracic echocardiography 
(often with portable or pocket size echo devices) is useful in patients with sudden hemodynamic 
instability to assess the rare occurrence of haemopericardium and tamponade. 
Electro anatomical mapping is another diagnostic tool used for diagnosis and to guide catheter 
ablation in AC patients with recurrent VT . This technique can be used to identify the abnormal 
low-voltage areas, which have been demonstrated to correspond to the loss of electrically active 
myocardium caused by fibro-fatty tissue, and is particular useful for differential diagnosis with 
idiopathic RV outflow tract tachycardia (64). 
Finally, the new AC criteria include the identification of a pathogenic mutation 
categorized as associated or probably associated with AC in the patient under evaluation. 
However, it has been emphasized that a pathogenic mutation is a DNA alteration associated with 
AC that alters or is expected to alter the encoded protein, is unobserved or rare in a large non–AC 
control population, and either alters or is predicted to alter the structure or function of the protein 
or has demonstrated linkage to the disease phenotype in a conclusive pedigree (so-called co-
segregation). Strict adherence to these criteria is essential, particularly at present with the advent 
of next generation sequencing. Moreover, recent data are supporting the concept that “genetic 
load” is often making the difference in disease penetrance, since many patients have more than 
one pathogenic variant.  
Key points: 
• Genetic data, endomyocardial biopsy and electro anatomical mapping are 
additional diagnostic techniques helpful in the evaluation of AC 
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9.  Imaging pre and post RF ablation  
Imaging methods play an important role in facilitating and guiding radiofrequency 
ablation procedures of arrhythmias and detecting complications during or after the procedure.  
Performing radiofrequency ablation procedures may be technically challenging due to complex 
anatomy or variable geometry of the involved cardiac structures.  Electroanatomical voltage maps 
can also be considered as an imaging technique, and is used for guiding RF ablation for VT. 
Recent advances in technology allow fusion of electroanatomical voltage maps with 3D 
morphological reconstructions from MDCT or CMR imaging to facilitate catheter manipulations. 
Identification of LGE by CMR correlates with foci of inducible ventricular tachyarrhythmia on 
electrophysiologic studies and may provide guidance for electroanatomic mapping and mode of 
ablation (e.g. endo- versus epicardial).(65) MDCT 3D-images, possibly integrated  into 3D-
EAM, are mainly helpful to evidence epicardial fat distribution, which correlates with low 
voltage and target ablation areas (clustering in the border of the fat region), and to avoid coronary 
arteries in the vicinity of target sites.(39)  
Complications of radiofrequency ablation are rare but potentially life-threatening. 
Ventricular perforation and cardiac tamponade occur in approximately 1% of ventricular RF 
ablation procedures,(66) but its risk may be higher in AC, where the RV wall may be weakened 
by fibro-fatty replacement.(67)  During or after ablation, transthoracic echocardiography (often 
with portable or pocket size echo devices or with intracardiac echo- when used for periprocedural 
monitoring) is useful in patients with sudden hemodynamic instability to assess 
haemopericardium/cardiac tamponade, thromboembolic events and acute ischemia from coronary 
artery lesions. Additionally, when an epicardial approach for VT ablation is used, ultrasound 
imaging may also be useful to detect iatrogenic lesions of abdominal organs or phrenic paralysis.  
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Key points: 
• Pre ablation multi modality imaging with fusion of electroanatomical voltage 
maps with 3D morphological reconstructions from multi-slice CT or CMR 
facilitate catheter manipulations 
• In patients with post ablation  hemodynamic instability, echocardiographic 
examination should be performed to evaluate possible haemopericardium, 
thromboembolic events and acute ischemia  
10. How to differentiate between AC from other arrhythmic diseases and 
acquired conditions:  
a. RVOT-VT  
The RVOT is the most common site of origin for idiopathic VT and frequent premature 
ventricular complexes (PVC) in patients with structurally normal hearts, known as RVOT-VT. In 
contrast to AC, RVOT-VT is usually a relatively benign condition, with generally well tolerated 
ventricular arrhythmias (5, 64). However, the RVOT area may also be origin of VT in patients 
with AC and in early stages of AC the distinction to RVOT-VT may be challenging. The 
treatment and prognosis differ substantially and an incorrect diagnosis may be devastating. 
Patients with RVOT-VT commonly have structurally normal ventricles, but frequent premature 
ventricular contractions (PVC) may cause myocardial remodeling with subsequent reduced 
function and dilatation, which further complicates the discrimination to AC. By cardiac imaging, 
fibro fatty replacement is not present in patients with RVOT-VT, while this is a hallmark of AC. 
Any findings of regional RV hypokinesia and dyskinesia by echo or CMR in addition to RVOT 
dilatation make the diagnosis of AC more probable and prognosis more severe (68).  
Other diagnostic tests include family history, which is normally negative in RVOT-VT 
patients; genetic testing for AC related mutations, and Holter monitoring. ECG markers for AC 
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as T-wave inversions in the precordial leads are absent in RVOT-VT patients. High numbers of 
VPC (> 9000 per 24 hours) in the absence of severe structural alterations increase the probability 
that the diagnosis is RVOT-VT and not AC (25).  In selected cases, electrovoltage anatomic 
mapping and endomyocardial biopsy can be determinant for differential diagnosis (64). 
Key points. 
• RVOT VT patients have more frequent PVC’s than AC patients and usually no 
structural or mechanical alterations 
b.  Sarcoidosis and myocarditis  
Patients with cardiac sarcoidosis or myocarditis have a few significantly different cardiac 
imaging characteristics when compared to patients with AC. The cardiac volume, in addition to 
the degree and location of cardiac involvement, can be used to distinguish between these disease 
entities. For instance, the presence of mediastinal lymphadenopathy, LV septal scar (LGE), 
significant LV dysfunction, and segmental areas of decreased uptake (201Thallium, 99-mTc 
Sestamibi, etc) in the ventricular myocardium that disappears or decrease in size during stress, 
and intense PET-FDG uptake in the myocardium should raise the suspicion for cardiac 
sarcoidosis(69). Consideration of cardiac sarcoidosis should be given if these imaging findings 
are observed during the evaluation for possible AC, particularly when conduction disturbances 
are also observed.  
In myocarditis the LV is most often involved and the RV is rarely affected selectively. 
Areas of segmental perfusion defects coupled with FDG uptake, local oedema (T2 weighted 
images), epicardial/mid-wall LGE on CMR, and the presence of severe global or regional 
hypokinesia without a specific coronary territory distribution are in favour of myocarditis, when 
clinically suspected(70). Of note, although endomyocardial biopsy is still considered the gold 
31 
 
standard, it can be inconclusive since these diseases tend to be focal(71). Higher sensitivity is 
achieved through imaging guided endomyocardial biopsy (72, 73). 
Key point. 
• Sarcoidosis can mimic AC. PET-FDG should be performed and a positive test 
raise the suspicion for cardiac sarcoidosis 
• Myocarditis may also mimic AC, and endomyocardial biopsy - although showing 
a low sensitivity - remains the gold standard for diagnosis 
 
c. Dilated cardiomyopathies  
Dilated cardiomyopathy may be particularly difficult to distinguish from non-classic 
(biventricular or left-dominant) forms of AC when there is early affection of the LV. 
Echocardiography has a limited role in this regard since LV dilation and/or systolic impairment 
are non-specific features. In many cases of left-dominant AC, LV structural abnormalities are 
localized in the posterolateral region (74, 75).  CMR may further aid to diagnosis by providing 
tissue characterization and identification of intra-myocardial fat and fibrosis in addition to 
assessment of LV morphology and function. While findings like mid-wall LGE may be observed 
in both left dominant AC and dilated cardiomyopathy, the subepicardial distribution favors AC 
(76). Moreover, LV fatty infiltration was shown to be a prevalent finding in AC, often involving 
the subepicardial LV lateral wall and resulting in myocardial wall thinning (33, 77) .  
Key points 
• Left dominant AC can mimic dilated cardiomyopathy. Frequent arrhythmias and 
subepicardial fibro-fatty replacement on CMR favors AC diagnosis.  
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d. Congenital heart diseases  
Congenital heart diseases with RV overload including anomalous venous drainage, ASD, 
are misdiagnosed as AC.  ECG changes may help correct diagnosis in addition to careful 
imaging. Heart catheterization may be necessary to detect potential shunts.   
e. Athlete’s heart 
RV and right atrium dilation are not specific to AC and is commonly found in athletes 
performing high-intensity exercise. Other important findings in athletes can be mild functional 
tricuspid regurgitation and dilation of the inferior vena cava (78) (79). These findings partly 
resemble echocardiographic findings in AC and can make it challenging to distinguish an athlete 
heart from AC by traditional cardiac imaging methods. Furthermore, athletic activity aggravates 
structural disease in AC patients which further complicate discrimination from athlete’s heart (53, 
80). RV cavity dilatation in athletes involves particularly RV inflow tract and is almost always 
associated with LV enlargement (“balanced enlargement”)(79). Typical findings in AC, like RV 
thinning, bulging, and aneurysms will normally not be found in athletes. Importantly, TAPSE is 
typically normal and no convincing differences in strain measurements are found even in dilated 
RV in athletes (81, 82) (83). AC or another type of RV cardiomyopathy should be suspected if 
RV strain values or TAPSE suggest a decreased RV function. (26, 84) CMR must always be 
requested if the diagnosis of AC is suspected in athletes. However, CMR RV alterations alone, 
without abnormalities on ECG and Holter, are uncommon in AC disease.  
Key points: 
• AC is aggravated by athletic activity 
• Abnormal measures of deformation imaging favor AC diagnosis 
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• CMR should be performed in unclear cases. CMR alterations alone, without 
abnormalities on ECG and Holter monitoring should favor athlete-induced 
changes and not AC diagnosis 
 
f. Brugada syndrome  
Although Brugada syndrome (BrS) is not associated with overt RV and LV structural 
abnormalities, endomyocardial biopsy, MDCT and CMR have identified mild RV 
abnormalities(85-89). In particular, RV wall motion abnormalities of the inferior wall have been 
detected by 2D echocardiography. A recent study has also shown in Brugada syndrome mild 
reduction of speckle tracking derived RV global longitudinal strain and of regional basal or mid 
RV free wall longitudinal strain which are, however, less pronounced than in AC (90, 91). Based 
on these findings, advanced cardiac imaging could be useful to distinguish Brugada syndrome 
from AC, in overlapping syndromes and when the clinical picture and ECG signs do not provide 
decisive elements for diagnosis.       
Key points 
• Overlap exists between AC and Brugada syndrome phenotypes including RV wall 
motion abnormalities. The clinical implication is unclear 
11. Potential future role of different imaging modalities in AC  
a. Echocardiography  
Assessment of RV function by standard 2D echocardiography is limited to the RV lateral 
wall and important parts of the RV are not visible by 2D echo. The role of 3D echocardiography 
in AC is not explored. The multislice display of the RV 3D data set may allow a more 
comprehensive assessment of RV regional wall motion independent on the tomographic view and 
taking into account all RV walls (Figure 6-10) (92). In addition, 3D echocardiography should be 
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used in future studies to improve the assessment of the entire RV, including volumes and 
function.(23, 30, 31)  
Strain imaging has a potential role in AC diagnosis and risk stratification for ventricular 
arrhythmias. By segmental analyses, regional dysfunction can be quantified and decreased strain 
values can confirm the visual impression of hypokinesia. Despite availability of normative 
values(29), issues about intervendor variability of strain values, reproducibility of regional strain 
and lack of standardization about the 2D view to be analyzed prevented absolute cut off values 
for segmental analyses to be established. Averaged RV strain from the 3 lateral RV segments 
may be a more robust measure of decreased function and previous studies have indicated that RV 
strain values worse than -25% may be markers of early disease and that values worse than -20% 
indicate severely reduced RV function(26, 53). Mechanical dispersion, reflecting dyssynchronous 
timing of contraction between different RV segments, may be used as an additional marker of 
early disease and interestingly also for arrhythmic risk stratification (26, 53).   
Modalities using simulation techniques may further improve imaging in future, but are not 
in clinical use currently. 
b. CMR  
AC is a heterogeneous heart muscle disorder and genotype-phenotype correlations are 
demonstrating that the spectrum of the disease is possibly broader. Although traditionally 
considered as RV disease, there is increasing evidence of biventricular or even isolated LV 
forms. LV involvement is an increasingly recognised entity that can be missed by other imaging 
modalities, but it can be easily detected on CMR as LGE, even in patients without a definite 
diagnosis of AC according to the current TFC, which in fact does not take into account the LV 
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dominant form (93). The new high-resolution quantitative T1 mapping and inter- and 
intraventricular RV dyssynchrony might be novel promising markers for the early detection of 
the disease. 
Key points 
• Echocardiographic strain analysis assesses regional function and shows added 
information in AC, but RV assessment is limited to a few segments. 
• 3DE will hopefully improve the assessment of RV regional wall motion, size and 
global function by echocardiography 
• CMR T1 mapping may be a novel promising marker for early AC disease 
 
c. PET/Nuclear 
As the current findings point towards the role of adrenergic dysfunction in AC, the neural 
imaging methods may play more important role in the future (12). There are established methods 
for both conventional nuclear medicine as well as PET to image cardiac innervation but more 
clinical trials are warranted. As we learn more about the mechanisms of the disease, also specific 
molecular imaging probes focusing on disease process can be developed. 
 
12. Summary 
 
In this expert consensus document, we have provided an overview of currently available  
imaging modalities and parameters to be used in diagnosis and follow up of patients evaluated for 
AC. We propose a wider spectrum of echocardiographic parameters which can increase the 
sensitivity of the modality for  AC. Furthermore, we have provided recommendations of imaging 
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use during follow up in AC patients and their family members. Finally, we have presented the 
most important differential diagnoses and how to distinguish these from AC.  
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Figure legends 
Figure 1. Proximal RV outflow diameters (RVOT PLAX and PSAX) and RV basal 
diameter (RVD) (diastole). Courtesy of Dr  J Saberniak 
Figure 2. A. RV fractional area change (RVFAC) calculated from RV  end diastolic area 
and B. from EV end systolic area as (RVEDA – RVESA/RVEDA) x 100)   C. Left dominant type 
of AC with  reduced LV function, LV dilatation, CMR showed epicardial fibrosis, ECG showed 
T inversion V1 – V6 and in inferior leads. The patients suffered from ventricular arrhythmia and 
was implanted with an ICD.  Courtesy of Dr.  J Saberniak 
 
Figure 3. Reduced longitudinal function in a patient with AC (TAPSE < 17mm , s’ 
tricuspid <9.5 cm/s) 
Figure 4. Reduced RV GLS in an AC patient 
Figure 5. Mechanical dispersion in AC. Compared to healthy volunteers, asymptomatic 
mutation carriers show increased TPSS-SD; compared to asymptomatic mutation carriers, overt 
dysfunction AC patients have high TPSS-SD (Sarvari et al, EHJ 2011) 
Figure 6-9. 3D TTE images showing the potential of this technique to diagnose AC: 
Figure 6. Subtricuspid valve aneurysm. Courtesy of Dr. D Muraru 
Figure 7. Multiplanar display of the sub tricuspid aneurism. Left upper= 4CH, Right 
upper: 2CH; Left lower = long axis; Right lower= short axis at the level of the aneurysm (blue 
dotted line on longitudinal views). Courtesy of Dr. D Muraru 
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Figure 8. 12 slice display of the subtricuspidal aneurysm. Courtesy of Dr. D Muraru 
Figure 9. Localized aneurysm. Left panel. RV focused apical 4CH view= normal;  Central 
panel. Cropped longitudinal apical view showing the localized aneurysm (yellow arrow); Right 
panel. En-face view of the entry orifice of the aneurysm. Courtesy of Dr. D Muraru 
Figure 10. Longitudinal (upper panels) and transversal (lower panels) cut planes showing 
the localized aneurysm (asterisk). Courtesy of Dr. D Muraru 
Figure 11.  CMR RVOT in and out view, cine image in end-diastole (A) and end-systole. 
Micro-aneurysms of the RVOT and RV diaphragmatic wall are present (white arrows).  
Figure 12. CMR Four-chamber view, LGE image (A) and corresponding image in cine 
end-diastolic frame (B). The white arrow shows myocardial LGE (fibrosis) of the RV free wall.  
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Table 1: Imaging criteria for AC from the Modified Task Force Criteria from 2010  
Global or regional dysfunction and structural alterations 
MAJOR 
  2D echo criteria 
Regional RV akinesia, dyskinesia or aneurysm and 1 of the following measured at end diastole. 
PLAX RVOT ≥32 mm 
PSAX RVOT ≥36 mm 
Fractional area change ≤33% 
  CMR criteria 
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and 1 of the following 
Ratio of RV end-diastolic volume to BSA ≥110 mL/m2 (male) or ≥100 mL/m2 (female) 
RV ejection fraction ≤40% 
  RV angiography criteria 
    Regional RV akinesia, dyskinesia or aneurysm 
MINOR 
  2D echo criteria 
    Regional RV akinesia or dyskinesia and 1 of the following measured at end diastole 
    PLAX RVOT  ≥29 to<32 mm  
    PSAX RVOT  ≥32 to<36 
    Fractional area change >33% to ≤40% 
CMR criteria 
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and 1 of the following 
Ratio of RV end-diastolic volume to BSA ≥100 to <110 mL/m2 (male) or ≥90 to <100 mL/m2 
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RV ejection fraction >40 to ≤45% 
 Diagnostic imaging criteria in AC modifyed from Marcus et al. AC:  Arrhythmogenic 
cardiomyopathy, BSA: Body surface area, PLAX RVOT: parasternal long axis right ventricular 
outflow tract, PSAX RVOT: parasternal short axis right ventricular outflow tract, RV: Right 
ventricle. 
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Table 2. Quantitative standard and advanced echocardiographic parameters (with 
respective cut-off points) recommended in patients with suspected or ascertained AC. (* indicates 
the TFC 2010 parameters)  
Parameter 
 
Abnormal if 
PLAX RVOT (mm) * ≥ 32  
PLAX RVOT index (mm/m2)* ≥ 19 
PSAX RVOT (mm) * ≥ 36 
PSAX RVOT index (mm2) * ≥ 21 
RV basal diameter (mm) >41  
RV fractional area change (%)* ≤ 33% 
TAPSE (mm)  < 17  
RV strain of lateral RV free wall (%) worse than -20 
RV mechanical dispersion (SD of Time to peak strain) (ms) > 25-30 # 
Three dimensional RV EF (%) ≤40 
LV GLS (%) worse than -18% 
# 3 segments model and 6 segments model. EF: Ejection fraction, GLS: Global 
longitudinal strain, LV: left ventricular, PLAX RVOT: parasternal long axis right ventricular 
outflow tract, PSAX RVOT: parasternal short axis right ventricular outflow tract, RV: Right 
ventricle, TAPSE: Tricuspid annular plane systolic excursion. 
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Table 3: Advantages and limitations of imaging techniques 
 
Echocardiography CMR CT Nuclear 
Advantages Large availability 
Assessment of 
structure and function 
If inadequate 
echocardiographic 
images and 
contraindications 
for CMR 
For research purposes 
 
New techniques (strain) 
Assess myocardial 
fibro-fatty 
replacement 
  
Limitations  Need of specific expertise  
Need of specific 
expertise 
Radiation 
 
Limited 
documentation  
 
Limited documentation 
 
Complex anatomy of the 
RV   
Complex anatomy of 
the RV   
Complex anatomy 
of the RV   
 
 
Load dependency of the 
RV 
Load dependency of 
the RV 
Load dependency 
of the RV 
 
 
Quantitative evaluation 
difficult 
Limited availability 
  
 
Limited value at the early 
stage 
Difficult at the early 
stage 
  
 
Risk of under diagnosis Risk of over diagnosis   
CMR: cardiac magnetic resonance, CT: computed tomography, RV: Right ventricle. 
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Table 4 Cardiac imaging tools for risk stratification of ventricular arrhythmias in AC 
Imaging technique Advantages Disadvantages 
2D Echocardiography Low cost                               
Large availability 
Low  reproducibility                
Suboptimal diagnostic accuracy 
Limited documentation                      
CMR  High reproducibility              
High diagnostic accuracy 
High cost                                  
Suboptimal availability  
Limited documentation                                           
1231-MIBG Promising diagnostic 
accuracy 
High cost                                  
Suboptimal availability            
Radiation exposure  
Limited documentation                      
 
CMR: cardiac magnetic resonance.   
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Table 5.  Cardiovascular imaging follow-up in patients with definite arrhythmogenic right 
ventricular cardiomyopathy diagnosis and in family members (mutation positive or first degree 
relatives from families without identified mutations)  
 Echocardiography CMR CT 
AC patients with ICD Clinically indicated Not indicated or 
Contraindicated* 
 
AC patients without 
ICD 
Clinical status and/or ECG 
changes or every 2-3 years 
First visit 
Clinical status and/or 
ECG changes and 
patients are difficult to 
explore at echo 
Patients who 
are difficult to 
assess  with 
echo and 
unsuitable for 
CMR 
Family members 
from  approximately 
10 years of age with 
borderline findings 
Clinical status or ECG 
changes or 1-2 years in 
subjects < 40 years of age. 
Every 2 years in subjects > 
40 years of age. 
First visit 
Every 1-2 years in 
subjects < 40 years of 
age or when 
indicated** 
Every 3-5 years or 
when indicated in 
subjects > 40 years of 
age** 
Patients who 
are difficult to 
assess  with 
echo and 
unsuitable for 
CMR 
Family members 
from approximately 
10 years of age 
without any 
morphological 
findings 
Clinical status or ECG 
changes or every 1-2 years 
in subjects < 40 years of age. 
Every 3-5 years in subjects > 
40 years of age** 
First visit 
Every 1-2 years in 
subjects < 40 years of 
age or when 
indicated** 
Every 3-5 years or 
when indicated in 
subjects > 40 years of 
Patients who 
are difficult to 
assess  with 
echo and 
unsuitable for 
CMR 
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age** 
*except in patients with CMR compatible devices; ** clinical or ECG changes suggestive 
of disease progression; AC, arrhythmogenic right ventricular cardiomyopathy; CMR, cardiac 
magnetic resonance; CT, multidetector computed tomography, ICD: implantable cardioverter 
defibrillator.  
